GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Pharma Ltd (XTAE:NTEC) » Definitions » 14-Day RSI

Intec Pharma (XTAE:NTEC) 14-Day RSI : 19.28 (As of May. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Intec Pharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-25), Intec Pharma's 14-Day RSI is 19.28.

The industry rank for Intec Pharma's 14-Day RSI or its related term are showing as below:

XTAE:NTEC's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 45.215 vs XTAE:NTEC: 19.28

Competitive Comparison of Intec Pharma's 14-Day RSI

For the Biotechnology subindustry, Intec Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intec Pharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intec Pharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Intec Pharma's 14-Day RSI falls into.



Intec Pharma  (XTAE:NTEC) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intec Pharma  (XTAE:NTEC) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Intec Pharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Intec Pharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Pharma (XTAE:NTEC) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.